Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer
April 20 2021 - 7:50AM
Business Wire
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage
biopharmaceutical company focused on discovering, acquiring,
developing and commercializing therapeutics in the disease areas of
immunology, inflammation and oncology, today announced that Luisa
Salter-Cid, Ph.D., Gossamer’s Chief Scientific Officer, is
resigning from Gossamer effective April 30, 2021. On that date,
Laura Carter, Ph.D., currently Gossamer’s Senior Vice President,
Research & Translational Biology, will be promoted to Chief
Scientific Officer.
“I would like to thank Luisa for her many contributions to
Gossamer Bio,” said Faheem Hasnain, Chairman, President and CEO of
Gossamer Bio. “Luisa has assembled a world-class research team that
has made significant progress in developing our pre-clinical
pipeline, and we wish her the best of luck as she moves on to new
endeavors.”
Dr. Salter-Cid has served as Chief Scientific Officer since
joining Gossamer in September 2018 following a distinguished career
at Bristol Myers Squibb.
“I am tremendously excited to welcome Laura Carter to the
executive management team,” said Mr. Hasnain. “Laura is a
brilliantly talented immunologist and a proven leader, and I look
forward to working together even more closely to develop the next
generation of clinical programs for Gossamer.”
Dr. Carter has over 20 years of industry experience spanning
target identification and validation activities through Phase 2
clinical trials in multiple therapeutic areas. Prior to joining
Gossamer in 2019, she was Senior Vice President, Biology at Lycera
Corporation, where she led the development of several immunology
and immuno-oncology clinical product candidates. Before joining
Lycera, she was a scientific director in the respiratory,
inflammation and autoimmunity group at MedImmune, where she was
responsible for overseeing research and development of treatments
for autoimmune diseases such as systemic lupus erythematosus (SLE),
rheumatoid arthritis and multiple sclerosis. Prior to MedImmune,
she was a senior research investigator in the inflammation biology
and translational science department at Array Biopharma. She
started her career in industry at Wyeth, where, among other
accomplishments, her basic science studies were critical in
identifying and characterizing the negative regulatory role of
PD-1:PD-L interactions on T cell function in vitro and in vivo.
Dr. Carter received an S.B. in biological science from
Massachusetts Institute of Technology and a Ph.D. in molecular
pathology from the University of California, San Diego School of
Medicine.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company
focused on discovering, acquiring, developing and commercializing
therapeutics in the disease areas of immunology, inflammation and
oncology. Its goal is to be an industry leader in each of these
therapeutic areas and to enhance and extend the lives of patients
suffering from such diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210420005195/en/
For Investors and Media: Bryan Giraudo, Chief Financial
Officer Gossamer Bio Investor Relations
ir@gossamerbio.com
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Apr 2023 to Apr 2024